Nutriband Advances Fentanyl Abuse-Deterrent Patch with FDA Meeting and Leadership Transition

The FDA has granted Nutriband Inc. a Type C Meeting for AVERSA™ Fentanyl to discuss the Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization, marking a significant regulatory milestone for the abuse-deterrent transdermal patch. This development occurs alongside a leadership transition where CEO Gareth Sheridan temporarily steps aside to pursue an Irish Presidential nomination, with Chairman Serguei Melnik assuming the interim CEO role during this critical phase.

The strategic partnership with Kindeva Drug Delivery combines proven FDA-approved fentanyl patch technology with Nutriband’s proprietary abuse-deterrent platform, targeting a peak U.S. market opportunity estimated between $80-200 million. This collaboration addresses the urgent medical need in pain management where balancing therapeutic benefit with abuse potential has become a regulatory priority amid the ongoing opioid crisis.

The pharmaceutical development landscape is experiencing a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. Innovations that enhance safety profiles of existing therapeutic options now represent the most significant patient impact, particularly in pain management where regulatory complexity requires both technological innovation and regulatory expertise to navigate approval pathways successfully.

The opioid crisis has fundamentally reshaped how regulators approach pain management solutions, creating opportunities at the intersection of proven therapeutic benefit and enhanced safety mechanisms. Nutriband’s progress with the FDA meeting and continued development under interim leadership demonstrates the company’s commitment to advancing solutions that address both medical needs and public health concerns surrounding opioid abuse.